原文 · 未翻译
Daily pill can double survival time for world’s deadliest cancer, trial shows
Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer
A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades.
Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late. More than half of patients are only diagnosed after it has spread.
Now experts at the world’s largest cancer conference are hailing the arrival of a smart drug called daraxonrasib, which they say could pave the way for a treatment revolution.
In the trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill doubled survival time, with fewer side-effects compared with chemotherapy. The findings were presented at the American Society of Clinical Oncology’s (Asco) annual meeting in Chicago.
Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy, the trial found.
“These results are landscape-changing,” said Dr Rachna Shroff, the chief of oncology at the University of Arizona Cancer Center and an Asco expert in gastrointestinal cancers, who was not involved with the study. “We are seeing unprecedented survival.”
When Shroff first read the results of the trial, led by researchers at the world-renowned Dana-Farber Cancer Institute in Boston, she wept, she said.
“Having treated pancreatic cancer for 16 years, I actually started crying in clinic. This is such an incredibly impactful study for our patients, and I really congratulate the [trial] investigators.”
Dr Julie Gralow, Asco’s chief medical officer and executive vice-president, who was also not involved with the trial, said it was a “gamechanger”. She added: “I’ve heard this study described as a home run. I would actually say it’s a grand slam.”
Daraxonrasib works by targeting a protein, Kras, that fuels nearly all pancreatic cancers. The drug glues molecules together to grab and shut down Kras.
Kras is part of the Ras family of genes. They can cause cancer cells to keep receiving signals to grow and divide, even when they should not. This can lead to cancer growing and spreading.
More than 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This is called a Ras G12 variant, and results in an overactive Kras protein.